Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis.
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial.
The influence of executive functions and memory on self-generation benefit in persons with multiple sclerosis.
Meta-Analysis of the Correlation Between Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis.
Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study.
Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.
Clinicopathological features in anterior visual pathway in neuromyelitis optica.
CD4+ T cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.
A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female Patients With Multiple Sclerosis.
Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
Antigen-Specific Binding of Multivalent Soluble Antigen Arrays Induces Receptor Clustering and Impedes B Cell Receptor Mediated Signaling.
ANALYSIS OF MULTIPLE SCLEROSIS LESIONS VIA SPATIALLY VARYING COEFFICIENTS.
The +190 G/A (rs1799864) polymorphism in the C-C chemokine receptor 2 (CCR2) gene is associated with susceptibility to multiple sclerosis in HLA-DRB1*15:01-negative individuals.
Genetic polymorphisms related to vitamin D and the therapeutic potential of vitamin D in multiple sclerosis.
Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders.
Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance.
Additive effect of prostaglandin E(2) and adenosine in mouse experimental autoimmune encephalomyelitis.
Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis.
Treatment of cognitive impairment in multiple sclerosis: position paper.
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons.
Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells.
Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder.
The Regulation of Reactive Changes Around Multiple Sclerosis Lesions by Phosphorylated Signal Transducer and Activator of Transcription.
Multiple sclerosis in 2013: Novel triggers, treatment targets and brain atrophy measures.
Pages
« first
‹ previous
…
446
447
448
449
450
451
452
453
454
…
next ›
last »